Zydus Cadila gets USFDA nod for anesthesia drug
Zydus Cadila said it has received an approval from the USFDA to market Succinylcholine Chloride injection, used as part of general anesthesia procedure, in the American market
New Delhi: Drug firm Zydus Cadila on Saturday said it has received an approval from the US health regulator to market Succinylcholine Chloride injection, used as part of general anesthesia procedure, in the American market.
The company has received an approval from the United States Food and Drug Administration (USFDA) to market its product in the US market, Zydus Cadila said in a statement.
The medication is used as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
The product would be manufactured at the group’s Moraiya, Ahmedabad-based formulations manufacturing facility.
The company said it has also received tentative approval for Plerixafor injection, used in treating certain type of blood cancers.
Zydus group now has more than 190 approvals from the USFDA and has so far filed over 320 abbreviated new drug applications (ANDAs) since the commencement of the filing process in financial year 2003-04.
- GAIL seeks to invest in start-ups solar power plants
- Jet Airways likely to sub-lease 7 ATR planes to TruJet
- Malaysia’s Axiata relinquishes major rights in Idea ahead of Vodafone merger
- BPCL Mumbai unit to remain shut for at least 2 months after fire
- Supertech to invest ₹800 crore this fiscal on various projects to deliver 10,000 flats
Editor's Picks »
- Rise in extreme weather events in India raises concerns over climate change impact
- US, China set to resume talks to resolve stand-off over trade
- NAA plans to knock on factory gates to enforce GST rate cuts
- Paintbrush meets pixel at India’s first Artificial Intelligence art show
- Water, vector-borne disease outbreak looms over Kerala